Celonic launches stand-alone GMP analytics portfolio

Find a job at Celonic

Challenging positions in upstream processing

CEMAX Technology

Celonic has engineered a technology that dramatically changes current strategies for development of API production cell lines. Current strategies are based on statistical integration of the DNA into the host genome. Celonic’s proprietary CEMAX technology leads to a targeted and stable integration of the DNA into the host genome with an assurance of high expression rates. Thus, CEMAX enables you to reduce the required number of cells for testing from thousands to just a few, offering a significant advantage in expenditure of time and costs.

Additionally, a satisfactory productivity is ensured. What counts most, is that CEMAX speeds the cell line development time – as well automatically the time-to-market – by about six months. Combined with Celonic’s proprietary technology for serum-free cultivation (> SEFEX), CEMAX accelerates time-to-clinic by up to nine months.

  • Cell line development within 4 weeks
  • Guarantee of high productivity
  • Serum-free process development ensures regulatory compliance
  • Smooth production of highly glycosylated proteins
  • Easily applicable for large scale

Key words: Cellonic, Contract Manufacturing Organization, Contract Analytic, Contract Research, Cell line development, stable high producer cell line, high producing cell line, regulatory conform, expression optimization, culture process optimization, USP, DSP, upstream process development, downstream process development, GMP, cGMP, non-GMP, GMP-like, GLP, GCP, manufacturing, GMP manufacturing license, animal tox study material, toxicology, biologic material, recombinant monoclonal antibody, recombinant protein, mammalian cell lines, cells, CHO, fast track cell line development, pre-clinical, clinical study material, market supply manufacturing, scale-up development, stainless steel stirred tank bioreactors, wave bioreactor, 1000 L scale, 300 L scale, serum free media, chemically defined media, cell culture media, transfection in serum free media, vector construction, mini pools, stability testing, MCB, Master Cell Bank, WCB, Working Cell Bank, PSB, Primary Seed Bank, research cell bank, Quality Control, HPLC for biologics, Protein A HPLC, parallel culturing systems, virus inactivation, validation batches, lots, downscale model, virus validation study, reference standard, pilot production, Drug Substance, Drug Product, specific Host Cell Protein assay, HCP, quality strategy, GLP-analytics, CHO K1, DG44, DHFR, biopharmaceuticals, HELA, HEK293, animal cells, CEMAX, SEFEX, biosimilar, biotechnology, EMA, EMEA, FDA, IgG, proof of concept, cultivation, suspension, adherent, cell growth, regulatory affairs, quality management, quality assurance, Wave bioreactors, immune therapeutics, cancer therapeutics, pharmaco kinetic, dynamic, large scale manufacturing, feeding strategy, dissolved oxygen, glucose level, human like glycosylation structure, glycosylation optimisation, tangential flow filtration, TFF, ultra-filtration, nano-filtration, virus-filtration, sterile filtration, Bioburden reduction, API formulation, formulation buffer study, amplification, cloning, sub-cloning, shaker flasks, spinner culture, 6-well-culture, fed-batch, perfusion, disposable bioreactors, cleaning validation, WFI, harvest, primary clone, documentation, SOP, instruction, Master Batch Record, quality management handbook, clean rooms, class C, 2-8°C, room temperature